Bausch + Lomb Corporation – New social media campaign from Bausch + Lomb aims to raise awareness that cataracts don’t wait

VAUGHAN – Bausch + Lomb Company (NYSE/TSX: BLCO) (‘Bausch + Lomb‘), a leading global eye health company dedicated to helping people see better to live better, has announced a new social media campaign designed to raise awareness about cataracts and the importance systematic screening for this treatable disease. The campaign will run throughout June during Cataract Awareness Month.

Cataract is the leading cause of vision loss in United States and the leading cause of blindness worldwide.1 Cataract surgery is one of the most common treatment options for cataracts, and although more than four million cataract surgeries are performed each year in United States alone, there are still affected individuals who may delay treatment out of fear.2,3

“As an ophthalmologist, I see firsthand the impact that delaying cataract treatment can have on people’s vision and lives,” said Catherine McCabeMD, CEO, Eye Health Americaand cataract and refraction surgeon, Sarasota, Florida. “Education is critically important to help alleviate the anxiety commonly felt by patients when considering cataract surgery, even though it is considered one of the safest and most most efficient in the world. United States.’3

Throughout the month of June, Bausch + Lomb publishes educational resources and content on its social media platforms under the hashtag #CataractsDontWait to raise cataract awareness and facilitate conversations between those potentially affected and their eye care professionals.

‘Bausch + Lomb is proud to educate the public about cataracts, their impact and the importance of routine screenings and not delaying treatment,” said Christina AckermanPresident, Ophthalmic Pharmaceuticals, Bausch + Lomb. “Through the campaign message, ‘Cataracts Don’t Wait,’ we hope to encourage early and appropriate discussions between those affected and their eye care professionals about potential treatment options to hopefully reduce the potential preventable vision loss.

About Cataract

A cataract is a clouding of the lens that blocks or alters the passage of light into the eye. The lens of the eye is located behind the pupil and the colored iris and is normally transparent. Vision may become blurry or dark because the cataract prevents light from passing through the retina properly. Typically, a cataract does not cause pain, redness, or tearing.4

In United States, it is estimated that more than 25 million Americans have cataracts, according to the report Future of Vision: Forecasting the Prevalence and Costs of Vision Problems. As the US population continues to age, the number of cataract cases is expected to increase by 50% to 38.5 million by 2032.5

About cataract surgery

An eye surgeon removes the cloudy lens and replaces it with a clear, artificial implant called an intraocular lens (IOL).6 According to the National Eye Institute of the United Statescataract surgery is one of the most common and effective surgical procedures performed in United States. In most cases, people see an improvement in vision after the procedure.7

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every stage of life. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb has its headquarters at Vaughan, Ontario with headquarters in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

Forward-looking statements

This press release may contain forward-looking statements, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, “intends”, “expects”, “should ‘, ‘could’, ‘would,’ ‘may,’ ‘believe,’ ‘estimate,’ ‘potential,’ ‘target’ or ‘continue’ and variations or similar expressions. These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s deposits with the US Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, the risks and uncertainties caused by or related to the evolution of the COVID-19 pandemic, as well as the fear of this pandemic and its potential effects, including the severity, duration and future impact are highly uncertain and cannot be predicted, and which could have a material adverse effect on Bausch + Lomb, including, but not limited to, its project development times, launches, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb assumes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.

Contact:

Investor

Arthur Shanon

Email: arthur.shannon@bauschhealth.com

Media

Lainie Keller

Email: lainie.keller@bauschhealth.com

Such. : (908) 927-1198